[go: up one dir, main page]

CN102605390B - Electroforming method for preparing degradable Fe-Zn alloy tubing for vascular stents - Google Patents

Electroforming method for preparing degradable Fe-Zn alloy tubing for vascular stents Download PDF

Info

Publication number
CN102605390B
CN102605390B CN201210091212.6A CN201210091212A CN102605390B CN 102605390 B CN102605390 B CN 102605390B CN 201210091212 A CN201210091212 A CN 201210091212A CN 102605390 B CN102605390 B CN 102605390B
Authority
CN
China
Prior art keywords
electroforming
alloy
prepared
solution
negative electrode
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201210091212.6A
Other languages
Chinese (zh)
Other versions
CN102605390A (en
Inventor
王伟强
齐民
王娟
陆山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dalian University of Technology
Original Assignee
Dalian University of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dalian University of Technology filed Critical Dalian University of Technology
Priority to CN201210091212.6A priority Critical patent/CN102605390B/en
Publication of CN102605390A publication Critical patent/CN102605390A/en
Application granted granted Critical
Publication of CN102605390B publication Critical patent/CN102605390B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Materials For Medical Uses (AREA)

Abstract

A method for preparing degradable Fe-Zn alloy pipes for vascular stents by electroforming belongs to the field of biological materials and electrochemical machining. The method is characterized in that: Fe-Zn alloy material is prepared by utilizing the competitive codeposition process of Fe and Zn ions, and the obtained alloy has fine grains and good comprehensive mechanical property; the thickness of the electroforming layer can reach 70 to 150 microns, and the electroforming layer is separated from the matrix and then used as an individual body for independent use, so that the seamless micro-tube for the bracket can be directly prepared, and the conventional pressure forming process of laser cutting of the metal micro-tube for the bracket is avoided; the component proportion of the Fe-Zn alloy is changed by adjusting electroforming parameters, the microstructure of the Fe-Zn alloy is changed by heat treatment, and the two aspects of synergistic effect can regulate and control the degradation rate of the Fe-Zn alloy material in human body fluid or blood and improve the mechanical property of the Fe-Zn alloy material. Therefore, the Fe-Zn alloy pipe for the intravascular stent with good biocompatibility, biological corrosion degradation performance and comprehensive mechanical property can be prepared by adopting the technology of the invention.

Description

电铸制备血管支架用可降解Fe-Zn合金管材的方法Electroforming method for preparing degradable Fe-Zn alloy tubing for vascular stents

技术领域technical field

本发明涉及一种在酸性溶液中电铸制备生物可降解Fe-Zn合金管材的方法,具体是指阳极铁溶解,溶液中的亚铁离子以及锌离子在阴极表面沉积制成铁锌合金型材的方法,属于生物医用材料和电化学加工领域。The invention relates to a method for preparing biodegradable Fe-Zn alloy pipes by electroforming in an acidic solution, specifically referring to the process of dissolving anode iron, depositing ferrous ions and zinc ions in the solution on the surface of the cathode to make iron-zinc alloy profiles The method belongs to the fields of biomedical materials and electrochemical processing.

背景技术Background technique

目前很多植入性医疗器械都是永久性的,这类器械往往会引起许多并发症,例如,永久性的不锈钢血管支架会导致植入部位血管的再狭窄,长期局部炎性反应等。而由生物医用可降解材料制成的器件在人体内完成功能使命后,会随着人的新陈代谢过程被降解吸收,不会对人体造成长期的影响,另外也可以在婴幼儿等处于快速生长发育的患者中使用。生物可降解金属材料由于具有良好的综合力学性能,是未来生物可降解材料的一个重要发展方向。铁是人体必不可少的微量元素,对人体的造血过程有重要作用,在血液中起到运输氧和营养物质的作用,能够促进细胞色素和各种酶的合成,是一种安全并且可吸收的金属材料。At present, many implantable medical devices are permanent, and such devices often cause many complications. For example, permanent stainless steel vascular stents can cause restenosis of blood vessels at the implantation site, long-term local inflammatory reactions, etc. After the devices made of biomedical degradable materials complete their functional missions in the human body, they will be degraded and absorbed along with the human metabolic process, and will not cause long-term effects on the human body. used in patients. Biodegradable metal materials are an important development direction of biodegradable materials in the future due to their good comprehensive mechanical properties. Iron is an essential trace element for the human body. It plays an important role in the hematopoietic process of the human body. It plays a role in transporting oxygen and nutrients in the blood, and can promote the synthesis of cytochromes and various enzymes. It is a safe and absorbable metal material.

经对现有文献的检索发现,Peuster等人在《Heart》(心脏)杂质2001年86卷第563-569页中报道了“A novel approach to temporary stenting:degradable cardiovascular stents produced from corrodiblemetal---results6—18months after implantation into New Zealand whiterabbits”(一种临时支撑血管的新方法:由可腐蚀金属制得的可降解心血管支架——支架植入新西兰白兔6-18个月的结果),他们试验了可降解铁支架(含铁>99.8%)的可靠性与安全性。结果显示,在6-18个月的随访期间,支架机械性能良好,无血栓事件发生。并且随着时间的延长,体液中Fe的含量不断增多,说明支架发生了降解过程。但在18个月的跟踪期内,支架仍没有完全降解,也会像不锈钢支架一样引起内膜增生,因此需要考虑将纯铁材料合金化,以加快其腐蚀降解速度。After searching the existing documents, it was found that Peuster et al reported "A novel approach to temporary stenting: degradable cardiovascular stents produced from corrodiblemetal---results6 —18months after implantation into New Zealand whiterabbits" (a new method of temporarily supporting blood vessels: a degradable cardiovascular stent made of corrodible metal-the results of 6-18 months of stent implantation into New Zealand white rabbits), they tested The reliability and safety of biodegradable iron stents (with iron>99.8%) were confirmed. The results showed that during the follow-up period of 6-18 months, the mechanical performance of the stent was good, and no thrombotic events occurred. And with the prolongation of time, the content of Fe in the body fluid continued to increase, indicating that the degradation process of the stent occurred. However, during the 18-month follow-up period, the stent has not completely degraded, and it will also cause intimal hyperplasia like stainless steel stents. Therefore, it is necessary to consider alloying pure iron materials to accelerate its corrosion degradation rate.

Zn元素的标准电极电位为-0.76V,Fe的标准电极电位为-0.44V,Zn作为合金元素加入到纯铁中,一方面可以和Fe形成固溶体以降低合金基体的电极电位,另一方面可以和Fe形成金属间化合物以增加合金中微阴极的数量,从而加快Fe基合金的降解速度。在生物学方面,Zn也是人体中必要的微量元素,在人体内的含量仅次于Fe。它对细胞的生长发育有着重要影响,是人体内数十种酶的主要成分,并且还与大脑发育和智力有关。所以,Zn加入Fe组成的合金还会有良好的生物医学安全性。但是,纯Fe熔点为1534℃,纯Zn的沸点为907℃,且在室温下,Zn在Fe中的溶解度很小,想通过常规冶炼方法制备这种高熔点差的合金时,会出现低熔点组元气化、蒸发等问题,难以控制合金的成分和质量。The standard electrode potential of Zn element is -0.76V, and the standard electrode potential of Fe is -0.44V. Zn is added to pure iron as an alloy element. On the one hand, it can form a solid solution with Fe to reduce the electrode potential of the alloy matrix. On the other hand, it can Form intermetallic compounds with Fe to increase the number of microcathodes in the alloy, thereby accelerating the degradation rate of Fe-based alloys. In terms of biology, Zn is also an essential trace element in the human body, and its content in the human body is second only to Fe. It has an important influence on the growth and development of cells, is the main component of dozens of enzymes in the human body, and is also related to brain development and intelligence. Therefore, the alloy composed of Zn added to Fe will also have good biomedical safety. However, the melting point of pure Fe is 1534°C, and the boiling point of pure Zn is 907°C, and at room temperature, the solubility of Zn in Fe is very small. When you want to prepare such an alloy with a high melting point difference by conventional smelting methods, a low melting point will appear. It is difficult to control the composition and quality of the alloy due to the gasification and evaporation of components.

电铸是在导体物质的表面,通过电解的方法制备一层薄的金属层的加工方法。它的原理与电镀技术类似,不同的是电铸金属层是与基体分离的,可以作为一个独立体使用。钢铁工业上已广泛应用电镀技术来制备Zn-Fe阳极保护性镀层(Fe的含量主要分布在0.4%~25%之间)。但至今未见利用电铸技术制备以Fe为主的生物医用Fe-Zn二元合金管材的报道。Electroforming is a processing method in which a thin metal layer is prepared by electrolysis on the surface of a conductor material. Its principle is similar to electroplating technology, the difference is that the electroformed metal layer is separated from the substrate and can be used as an independent body. Electroplating technology has been widely used in the iron and steel industry to prepare Zn-Fe anode protective coating (the content of Fe is mainly distributed between 0.4% and 25%). But so far there is no report on the preparation of biomedical Fe-Zn binary alloy pipes mainly composed of Fe by electroforming technology.

发明内容Contents of the invention

为了克服现有技术中的不足,本发明提供一种使用电铸技术制备血管支架用可降解Fe-Zn合金管材的方法。该方法应利用电解质中的Fe、Zn正离子在电场作用下向阴极互竞共沉积的过程制备出生物可降解的Fe-Zn合金;并且可以通过调整电化学参数,电解液中的离子浓度配比,以及pH、温度,来改变Fe-Zn合金的成分配比,使Zn的质量比在1~40%之间变化;还可通过随后的固溶和时效析出热处理来控制合金的微观组织结构,从而达到调控该材料在人体体液或血液中降解速率,改善材料力学性能的目的。In order to overcome the deficiencies in the prior art, the present invention provides a method for preparing degradable Fe-Zn alloy tubes for vascular stents using electroforming technology. The method should utilize the process of Fe and Zn positive ions in the electrolyte to compete and co-deposit to the cathode under the action of an electric field to prepare a biodegradable Fe-Zn alloy; and the ion concentration in the electrolyte can be adjusted by adjusting the electrochemical parameters. Ratio, as well as pH and temperature, to change the composition ratio of Fe-Zn alloy, so that the mass ratio of Zn can be changed between 1 and 40%; the microstructure of the alloy can also be controlled by subsequent solid solution and aging precipitation heat treatment , so as to achieve the purpose of regulating the degradation rate of the material in human body fluid or blood and improving the mechanical properties of the material.

本发明采用的技术方案是:一种电铸制备血管支架用可降解Fe-Zn合金管材的方法采用以下步骤:The technical scheme adopted in the present invention is: a kind of electroforming method that prepares degradable Fe-Zn alloy tubing for vascular stent adopts the following steps:

a.配制电铸液,电铸液组分为:去离子水1000g、氯化亚铁200~300g、氯化锌1~50g、十二烷基硫酸钠0.01~0.5g、柠檬酸钠5~30g、抗坏血酸1~2g、氯化钠10~20g、氯化锰1~5g;a. Prepare electroforming solution, the components of electroforming solution are: deionized water 1000g, ferrous chloride 200~300g, zinc chloride 1~50g, sodium lauryl sulfate 0.01~0.5g, sodium citrate 5~ 30g, 1-2g ascorbic acid, 10-20g sodium chloride, 1-5g manganese chloride;

b.用氢氧化钠和盐酸来调节溶液的pH,使pH保持在3.0~4.0;b. Use sodium hydroxide and hydrochloric acid to adjust the pH of the solution to keep the pH at 3.0-4.0;

c.电铸阴极在通电之前进行前处理,包括除油,清洗,弱浸蚀;c. Electroformed cathodes are pre-treated before being energized, including degreasing, cleaning, and weak etching;

d.采用直流电源或脉冲电源进行电铸,保证阴极电流密度为1.0~3.0A/dm2,电铸液的温度保持在30~40℃,电铸过程中加以机械搅拌;d. Use DC power supply or pulse power supply for electroforming to ensure that the cathode current density is 1.0-3.0A/dm 2 , the temperature of the electroforming solution is kept at 30-40°C, and mechanical stirring is added during the electroforming process;

e.电铸完成后,将带有电铸合金层的低熔点阴极芯模加热熔化掉,得到Zn元素质量百分比为1~40%的Fe-Zn合金管材。e. After the electroforming is completed, the low-melting-point cathode mandrel with the electroforming alloy layer is heated and melted to obtain a Fe-Zn alloy pipe with a Zn element mass percentage of 1-40%.

上述技术方案中,所述电铸阴极芯模为熔点低于400℃的金属丝,其直径与制备血管支架的直径相匹配;电铸阳极形状为环状,且以阴极芯模为中心轴放置,其材料为纯铁,纯度不小于99.9%。In the above technical solution, the electroformed cathode mandrel is a metal wire with a melting point lower than 400°C, and its diameter matches the diameter of the prepared vascular stent; the shape of the electroformed anode is ring-shaped, and the cathode mandrel is placed as the central axis , its material is pure iron with a purity not less than 99.9%.

本发明的有益效果是:这种电铸制备血管支架用可降解Fe-Zn合金管材的方法与现有的制备生物可降解材料的方法相比,其特点是:The beneficial effects of the present invention are: compared with the existing method for preparing biodegradable materials, the method for electroforming the degradable Fe-Zn alloy tubing for vascular stents is characterized by:

1)避免了Fe和Zn两种元素物理性质相差大所带来的常规合金化制备问题,利用Fe和Zn离子的互竞共沉积过程制备Fe-Zn合金材料,并且得到的合金具有细小的晶粒,综合力学性能良好。1) To avoid the problem of conventional alloying preparation caused by the large difference in the physical properties of Fe and Zn, the Fe-Zn alloy material is prepared by using the competitive co-deposition process of Fe and Zn ions, and the obtained alloy has fine crystals Granules with good comprehensive mechanical properties.

2)电铸层的厚度可以达到70微米到150微米,与基体分离后作为个体单独使用,因此可以直接制得支架用无缝微细管材,避免了激光切割支架用金属微细管的常规压力成型工序。2) The thickness of the electroformed layer can reach 70 microns to 150 microns, and it can be used as an individual after being separated from the substrate. Therefore, seamless micro-tubes for stents can be directly produced, avoiding the conventional pressure forming process of laser cutting metal micro-tubes for stents .

3)通过调节电铸参数改变Fe-Zn合金的成分配比,热处理改变Fe-Zn合金的微观组织结构,这两方面协同作用可以调控Fe-Zn合金材料在人体体液或者血液中的降解速率,并改善其力学性能。因此采用本发明技术可以制备出具有良好生物相容性、生物腐蚀降解性能和综合力学性能的血管支架用Fe-Zn合金管材。3) Change the composition ratio of Fe-Zn alloy by adjusting electroforming parameters, and change the microstructure of Fe-Zn alloy by heat treatment. The synergistic effect of these two aspects can regulate the degradation rate of Fe-Zn alloy materials in human body fluid or blood. and improve its mechanical properties. Therefore, the technology of the present invention can be used to prepare Fe-Zn alloy tubes for blood vessel stents with good biocompatibility, biocorrosion degradation performance and comprehensive mechanical properties.

附图说明Description of drawings

图1为电铸制备血管支架用可降解Fe-Zn合金管材的设备示意图。Fig. 1 is a schematic diagram of the equipment for electroforming the degradable Fe-Zn alloy tubing for vascular stents.

图中:1、电铸槽;2、电铸液;3、环形纯铁阳极;4、阴极芯模;5、Fe-Zn合金电铸层。In the figure: 1. Electroforming tank; 2. Electroforming solution; 3. Annular pure iron anode; 4. Cathode mandrel; 5. Fe-Zn alloy electroforming layer.

具体实施方式Detailed ways

下面用具体实施例结合附图对本发明作进一步的详细说明,但并不意味着对本发明保护内容的任何限定。The present invention will be further described in detail below with specific embodiments in conjunction with the accompanying drawings, but it does not imply any limitation to the protection content of the present invention.

实施例1Example 1

a.在电铸槽1中配制电铸液2,电铸液2包括:去离子水1000g、氯化亚铁300g、氯化锌10g、十二烷基硫酸钠0.02g、柠檬酸钠20g、抗坏血酸1.5g、氯化钠15g、氯化锰5g;a. prepare electroforming solution 2 in electroforming tank 1, electroforming solution 2 includes: deionized water 1000g, ferrous chloride 300g, zinc chloride 10g, sodium lauryl sulfate 0.02g, sodium citrate 20g, Ascorbic acid 1.5g, sodium chloride 15g, manganese chloride 5g;

b.用氢氧化钠和盐酸来调节溶液的pH,使pH保持在3.5;b. adjust the pH of the solution with sodium hydroxide and hydrochloric acid to keep the pH at 3.5;

c.采用直流电源进行电铸。接电源负极的为阴极芯模4,其所用材料为金属锡丝,丝的直径为1.8mm,其没入电解液中,能够生成均匀Fe-Zn合金电铸层5的有效长度为40mm。接电源正极的为环形纯铁阳极3,其纯度为99.9%。阴极芯模4放置在环形纯铁阳极3的中心轴上,以保证电铸管材壁厚的均匀性。阴极芯模4在通电之前进行前处理,包括除油,清洗,弱浸蚀;c. Using DC power supply for electroforming. The cathode mandrel 4 connected to the negative pole of the power supply is made of metal tin wire with a diameter of 1.8 mm, which is submerged in the electrolyte to generate a uniform Fe-Zn alloy electroforming layer 5 with an effective length of 40 mm. The one connected to the positive pole of the power supply is an annular pure iron anode 3 with a purity of 99.9%. The cathode mandrel 4 is placed on the central axis of the annular pure iron anode 3 to ensure the uniformity of the wall thickness of the electroformed pipe. The cathode mandrel 4 is pre-treated before power-on, including degreasing, cleaning, and weak etching;

d.保证阴极恒电流密度为1.5A/dm2,电铸液2的温度保持在35℃,电铸过程中采用机械搅拌,电铸时间4h;d. Ensure that the cathode constant current density is 1.5A/dm 2 , the temperature of the electroforming solution 2 is kept at 35°C, mechanical stirring is used during the electroforming process, and the electroforming time is 4 hours;

e.电铸完成后,将带有Fe-Zn合金电铸层5的阴极芯模4利用加热装置加热,熔去阴极芯模4,最后经清洗打磨得到锌含量为15%,长度为40mm,内径为1.8mm,壁厚为0.1mm的Fe-Zn合金薄壁微细管材。e. After the electroforming is completed, the cathode mandrel 4 with the Fe-Zn alloy electroforming layer 5 is heated by a heating device, and the cathode mandrel 4 is melted away. Finally, the zinc content is 15% and the length is 40 mm after cleaning and polishing. Fe-Zn alloy thin-walled fine tubes with an inner diameter of 1.8mm and a wall thickness of 0.1mm.

该合金管材再经750℃固溶处理10min,水淬,250℃时效5h。最后得到的合金材料,其抗拉强度为350MPa,断后伸长率为20%。在模拟体液中经90天浸泡测试得到其腐蚀降解速度为0.7mmy-1The alloy pipe is subjected to solution treatment at 750°C for 10 minutes, quenched in water, and aged at 250°C for 5 hours. The finally obtained alloy material has a tensile strength of 350 MPa and an elongation after fracture of 20%. The corrosion degradation rate is 0.7mmy -1 after immersion test in simulated body fluid for 90 days.

实施例2Example 2

a.在电铸槽1中配制电铸液2,电铸液2包括:去离子水1000g、氯化亚铁300g、氯化锌7g、十二烷基硫酸钠0.02g、柠檬酸钠20g、抗坏血酸1.5g、氯化钠15g、氯化锰5g;a. prepare electroforming solution 2 in electroforming tank 1, electroforming solution 2 includes: deionized water 1000g, ferrous chloride 300g, zinc chloride 7g, sodium lauryl sulfate 0.02g, sodium citrate 20g, Ascorbic acid 1.5g, sodium chloride 15g, manganese chloride 5g;

b.用氢氧化钠和盐酸来调节溶液的pH,使pH保持在3.5;b. adjust the pH of the solution with sodium hydroxide and hydrochloric acid to keep the pH at 3.5;

c.采用直流电源进行电铸。接电源负极的为阴极芯模4,其所用材料为金属锡丝,丝的直径为1.8mm,其没入电解液中,能够生成均匀Fe-Zn合金电铸层5的有效长度为40mm。接电源正极的为环形纯铁阳极3,其纯度为99.9%。阴极芯模4放置在环形纯铁阳极3的中心轴上,以保证电铸管材壁厚的均匀性。阴极芯模4在通电之前进行前处理,包括除油,清洗,弱浸蚀;c. Using DC power supply for electroforming. The cathode mandrel 4 connected to the negative pole of the power supply is made of metal tin wire with a diameter of 1.8 mm, which is submerged in the electrolyte to generate a uniform Fe-Zn alloy electroforming layer 5 with an effective length of 40 mm. The one connected to the positive pole of the power supply is an annular pure iron anode 3 with a purity of 99.9%. The cathode mandrel 4 is placed on the central axis of the annular pure iron anode 3 to ensure the uniformity of the wall thickness of the electroformed pipe. The cathode mandrel 4 is pre-treated before power-on, including degreasing, cleaning, and weak etching;

d.保证阴极恒电流密度为1.5A/dm2,电铸液2的温度保持在35℃,电铸过程中采用机械搅拌,电铸时间4h;d. Ensure that the cathode constant current density is 1.5A/dm 2 , the temperature of the electroforming solution 2 is kept at 35°C, mechanical stirring is used during the electroforming process, and the electroforming time is 4 hours;

e.电铸完成后,将带有Fe-Zn合金电铸层5的阴极芯模4利用加热装置加热,熔去阴极芯模4,最后经清洗打磨得到锌含量为10%,长度为40mm,内径为1.8mm,壁厚为0.1mm的Fe-Zn合金薄壁微细管材。e. After the electroforming is completed, the cathode mandrel 4 with the Fe-Zn alloy electroforming layer 5 is heated by a heating device, and the cathode mandrel 4 is melted away. Finally, the zinc content is 10% and the length is 40 mm after cleaning and polishing. Fe-Zn alloy thin-walled fine tubes with an inner diameter of 1.8mm and a wall thickness of 0.1mm.

该合金管材再经680℃固溶处理10min,水淬,250℃时效5h。最后得到的合金材料,其抗拉强度为320MPa,断后伸长率为23%。在模拟体液中经90天浸泡测试得到其腐蚀降解速度为0.58mmy-1The alloy pipe is then subjected to solution treatment at 680°C for 10 minutes, quenched in water, and aged at 250°C for 5 hours. The finally obtained alloy material has a tensile strength of 320MPa and an elongation after fracture of 23%. The corrosion degradation rate is 0.58mmy -1 after immersion test in simulated body fluid for 90 days.

Claims (2)

1. a method for degradable Fe-Zn alloy pipe for intravascular stent is prepared in electroforming, it is characterized in that: adopt following steps:
A. prepare electroforming solution, electroforming solution component is: deionized water 1000g, iron protochloride 200~300g, zinc chloride 1~50g, sodium lauryl sulphate 0.01~0.5g, Trisodium Citrate 5~30g, xitix 1~2g, sodium-chlor 10~20g, Manganous chloride tetrahydrate 1~5g;
B. with sodium hydroxide and hydrochloric acid, carry out the pH of regulator solution, make pH remain on 3.0~4.0;
C. electroforming negative electrode carried out pre-treatment before energising, comprised oil removing, cleaned weak etch;
D. adopt direct supply or the pulse power to carry out electroforming, guarantee that cathode current density is 1.0~3.0A/dm 2, the temperature of electroforming solution remains on 30~40 ℃, mechanical stirring in addition in electroforming process;
E. after electroforming completes, the low melting point negative electrode core heat fused with electromolding alloy layer is fallen, obtained the Fe-Zn alloy pipe that Zn element mass percent is 1~40%.
2. the method for degradable Fe-Zn alloy pipe for intravascular stent is prepared in electroforming according to claim 1, it is characterized in that: described electroforming negative electrode core is fusing point lower than the wire of 400 ℃, and its diameter matches with the diameter of preparing intravascular stent; Electroforming anode shape is ring-type, and axle is placed centered by negative electrode core, and its material is pure iron, and purity is not less than 99.9%.
CN201210091212.6A 2012-03-31 2012-03-31 Electroforming method for preparing degradable Fe-Zn alloy tubing for vascular stents Expired - Fee Related CN102605390B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210091212.6A CN102605390B (en) 2012-03-31 2012-03-31 Electroforming method for preparing degradable Fe-Zn alloy tubing for vascular stents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210091212.6A CN102605390B (en) 2012-03-31 2012-03-31 Electroforming method for preparing degradable Fe-Zn alloy tubing for vascular stents

Publications (2)

Publication Number Publication Date
CN102605390A CN102605390A (en) 2012-07-25
CN102605390B true CN102605390B (en) 2014-08-13

Family

ID=46523138

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210091212.6A Expired - Fee Related CN102605390B (en) 2012-03-31 2012-03-31 Electroforming method for preparing degradable Fe-Zn alloy tubing for vascular stents

Country Status (1)

Country Link
CN (1) CN102605390B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3087958B1 (en) 2013-12-24 2019-10-30 Nipro Corporation Stent
CN104689369B (en) * 2015-03-13 2017-06-30 西安爱德万思医疗科技有限公司 A kind of tough Zn-Fe systems kirsite of the degradable corrosion-proof and high-strength of human body and its application
CN106492293B (en) * 2016-11-18 2019-08-30 南京理工大学 A kind of preparation method of titanium micro tube for biological stent
CN106757198B (en) * 2016-12-16 2019-09-27 中色科技股份有限公司 Method for preparing porous aluminum with uniform coating and without crack generation
CN109200342A (en) * 2017-07-06 2019-01-15 先健科技(深圳)有限公司 Implantable device
CN109234769A (en) * 2018-10-09 2019-01-18 福建夜光达科技股份有限公司 A kind of preparation method of ultra-thin metal layer
CN109321955B (en) * 2018-12-14 2020-01-24 大连理工大学 A kind of electrodeposited Fe-Zn alloy plating solution
DE102020121729B4 (en) 2020-08-19 2023-11-02 Leibniz-Institut für Festkörper- und Werkstoffforschung Dresden e.V. (IFW Dresden e.V.) Implant material and its use
CN112914538A (en) * 2021-03-29 2021-06-08 重庆科技学院 Blood vessel blood flow volume acquisition device and method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5772864A (en) * 1996-02-23 1998-06-30 Meadox Medicals, Inc. Method for manufacturing implantable medical devices
CN101085377A (en) * 2007-06-11 2007-12-12 沈阳工业大学 Process for forming magnesium alloy ultra-fine thin-wall tube used for degradable blood vessel bracket

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268382B2 (en) * 2010-07-12 2012-09-18 Medtronic Vascular, Inc. Method of making a stent with hollow struts
JP5713336B2 (en) * 2010-08-12 2015-05-07 株式会社オプトニクス精密 Stent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5772864A (en) * 1996-02-23 1998-06-30 Meadox Medicals, Inc. Method for manufacturing implantable medical devices
CN101085377A (en) * 2007-06-11 2007-12-12 沈阳工业大学 Process for forming magnesium alloy ultra-fine thin-wall tube used for degradable blood vessel bracket

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Electroformed iron as new biomaterial for degradable stents: Development process and structure–properties relationship;M. Moravej等;《Acta Biomaterialia》;20101231(第6期);1726-1735 *
M. Moravej等.Electroformed iron as new biomaterial for degradable stents: Development process and structure–properties relationship.《Acta Biomaterialia》.2010,(第6期),1726-1735.

Also Published As

Publication number Publication date
CN102605390A (en) 2012-07-25

Similar Documents

Publication Publication Date Title
CN102605390B (en) Electroforming method for preparing degradable Fe-Zn alloy tubing for vascular stents
Moravej et al. Effect of electrodeposition current density on the microstructure and the degradation of electroformed iron for degradable stents
CN110029383B (en) Degradable zinc-copper foam biological material
CN101485900B (en) Degradable Mg-Zn-Zr alloy endovascular stent and comprehensive processing technique thereof
CN103498129B (en) A kind of iron ion injects deposition carries out surface modification method to biological degradation Magnesium and magnesium alloys
Xu et al. The enhancement of mechanical properties and uniform degradation of electrodeposited Fe-Zn alloys by multilayered design for biodegradable stent applications
Geng et al. Corrosion resistance and degradation behavior of anodized Mg-Gd alloys: A comparative study
CN102181842A (en) Method for modifying titanium surface
CN102634725A (en) A biomedical corrosion-degradable binary Fe-Zn alloy material
CN101703797A (en) Fluorine-substituted apatite coating on surface of biologic medical magnesium or alloy thereof and preparation method
CN109758605B (en) Magnesium alloy surface fine needle-shaped hydroxyapatite micro-nano structure coating and preparation method thereof
CN105177645A (en) Preparation method of multi-layer composite gradient nano pure copper materials
CN107236983A (en) A kind of preparation method of ferroso-ferric oxide/titanium dioxide magnetic bio active coating
Ji et al. Research status and future prospects of biodegradable Zn-Mg alloys
CN107119304A (en) A kind of magnetic TiO2The differential arc oxidation preparation method of bioactivity coatings
CN103695977A (en) Electroplating method capable of enabling tin coating to be level and preventing tin whisker from growing
CN103498184B (en) A kind of biological medical magnesium alloy differential of the arc electrophoresis method of modifying
CN108714252B (en) Preparation method of magnesium alloy fixing screw capable of being degraded controllably in vivo
CN104878362A (en) Method for modifying surfaces of biodegradable magnesium and magnesium alloy through titanium ion implantation and deposition
CN109082689B (en) Magnesium alloy implant material with nanocrystalline zinc coating on surface and preparation method thereof
Sadeghi et al. Thick rhodium electrodeposition on copper backing as the target for production of palladium-103
WO2024022535A1 (en) Electroplated part and manufacturing method therefor, fixture for manufacturing, and apparatus
Wang et al. Microstructure and in vitro biodegradable properties of Fe-Zn alloys prepared by electroforming
CN114921833A (en) A kind of medical pure zinc material and its preparation method and application
CN108560036B (en) A kind of magnesium alloy material with Zn2+ on the surface and its preparation method and application

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140813

CF01 Termination of patent right due to non-payment of annual fee